Baidu
map

重磅消息,第十一届药典委员会成立!(附组成人员名单)

2017-08-30 CFDA CFDA

根据《中华人民共和国药品管理法》的规定,为做好《中华人民共和国药典》2020年版编制及其他国家药品标准的制定和修订工作,总局决定成立第十一届药典委员会。本届药典委员会由405名委员组成,设执行委员会和26个专业委员会。



根据《中华人民共和国药品管理法》的规定,为做好《中华人民共和国药典》2020年版编制及其他国家药品标准的制定和修订工作,总局决定成立第十一届药典委员会。本届药典委员会由405名委员组成,设执行委员会和26个专业委员会。

其中,毕井泉任主任委员,吴浈任常务副主任委员,张伯礼、陈凯先、曹雪涛任副主任委员,张伟任秘书长。

执行委员包括丁丽霞等67人;委员包括丁野等320人;顾问委员包括王永炎18人。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804834, encodeId=8ff11804834d8, content=<a href='/topic/show?id=b83de7651cc' target=_blank style='color:#2F92EE;'>#组成人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77651, encryptionId=b83de7651cc, topicName=组成人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Mon Oct 23 15:07:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540022, encodeId=bcdf154002223, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Fri Sep 01 10:07:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549170, encodeId=cb8a15491e060, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri Sep 01 10:07:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804834, encodeId=8ff11804834d8, content=<a href='/topic/show?id=b83de7651cc' target=_blank style='color:#2F92EE;'>#组成人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77651, encryptionId=b83de7651cc, topicName=组成人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Mon Oct 23 15:07:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540022, encodeId=bcdf154002223, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Fri Sep 01 10:07:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549170, encodeId=cb8a15491e060, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri Sep 01 10:07:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 lsj632
  3. [GetPortalCommentsPageByObjectIdResponse(id=1804834, encodeId=8ff11804834d8, content=<a href='/topic/show?id=b83de7651cc' target=_blank style='color:#2F92EE;'>#组成人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77651, encryptionId=b83de7651cc, topicName=组成人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Mon Oct 23 15:07:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540022, encodeId=bcdf154002223, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Fri Sep 01 10:07:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549170, encodeId=cb8a15491e060, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Fri Sep 01 10:07:00 CST 2017, time=2017-09-01, status=1, ipAttribution=)]
    2017-09-01 xxxx1054
Baidu
map
Baidu
map
Baidu
map